Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Soleno Therapeutics (NASDAQ: SLNO), a clinical-stage biopharmaceutical company focused on rare disease treatments, has announced inducement grants to six new employees as required by Nasdaq Stock Market rules. The company's independent board members approved non-qualified stock options to purchase 143,850 shares of common stock. These options have exercise prices of $49.52 and $48.44 per share, matching Soleno's closing stock prices on August 13 and 16, 2024, respectively.
The option awards will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter, contingent on continued employment. These grants fall under Soleno's 2020 Inducement Equity Incentive Plan and are designed to attract and retain talent in compliance with Nasdaq Listing Rule 5635(c)(4).
Soleno Therapeutics (NASDAQ: SLNO), un'azienda biofarmaceutica in fase clinica focalizzata sui trattamenti per malattie rare, ha annunciato concessioni di incentivazione a sei nuovi dipendenti come richiesto dalle normative del Nasdaq Stock Market. I membri indipendenti del consiglio di amministrazione dell'azienda hanno approvato opzioni su azioni non qualificate per acquistare 143.850 azioni di azioni ordinarie. Queste opzioni hanno prezzi di esercizio di $49.52 e $48.44 per azione, in linea con i prezzi di chiusura delle azioni di Soleno del 13 e 16 agosto 2024, rispettivamente.
Le assegnazioni di opzioni matureranno in quattro anni, con il 25% che matura dopo un anno e il resto che matura mensilmente successivamente, a condizione di un impiego continuativo. Queste concessioni rientrano nel Piano di Incentivazione Azionaria di Inducimento del 2020 di Soleno e sono progettate per attrarre e trattenere talenti in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Soleno Therapeutics (NASDAQ: SLNO), una empresa biofarmacéutica en etapa clínica enfocada en tratamientos para enfermedades raras, ha anunciado subvenciones de inducimiento a seis nuevos empleados, tal como lo requieren las normas del Nasdaq Stock Market. Los miembros independientes de la junta de la compañía aprobaron opciones sobre acciones no calificadas para adquirir 143,850 acciones de acciones comunes. Estas opciones tienen precios de ejercicio de $49.52 y $48.44 por acción, coincidiendo con los precios de cierre de las acciones de Soleno del 13 y 16 de agosto de 2024, respectivamente.
Las concesiones de opciones se consolidarán en cuatro años, con el 25% consolidándose después de un año y el resto consolidándose mensualmente a partir de entonces, condicionado al empleo continuo. Estas subvenciones están bajo el Plan de Incentivo de Capital por Inducimiento de 2020 de Soleno y están diseñadas para atraer y retener talento en cumplimiento con la Regla de Cotización Nasdaq 5635(c)(4).
솔레노 테라퓨틱스(SNASDAQ: SLNO)는 희귀질환 치료에 중점을 둔 임상 단계의 생명공학 회사로, 나스닥 주식 시장 규정에 따라 여섯 명의 신규 직원에게 유인 보상을 발표했습니다. 회사의 독립 이사들은 143,850주의 보통주를 구매할 수 있는 비상장 주식 옵션을 승인했습니다. 이 옵션의 행사 가격은 $49.52 및 $48.44으로, 각각 2024년 8월 13일 및 16일에 솔레노의 종가와 일치합니다.
옵션 보상은 4년 동안 유예됩니다, 1년 후 25%가 유예되고 이후 매달 나머지가 유예되며, 계속 근무하는 데 조건이 붙습니다. 이러한 보상은 솔레노의 2020년 유인 주식 인센티브 계획에 포함되며, 나스닥 상장 규칙 5635(c)(4)에 따라 인재를 유치하고 유지하기 위해 설계되었습니다.
Soleno Therapeutics (NASDAQ: SLNO), une entreprise biopharmaceutique en phase clinique axée sur les traitements des maladies rares, a annoncé des subventions d'incitation à six nouveaux employés, comme l'exigent les règles du Nasdaq Stock Market. Les membres indépendants du conseil d'administration de l'entreprise ont approuvé des options d'actions non qualifiées pour acheter 143 850 actions ordinaires. Ces options ont des prix d'exercice de $49.52 et $48.44 par action, correspondant respectivement aux prix de clôture des actions de Soleno les 13 et 16 août 2024.
Les attributions d'options seront acquises sur une période de quatre ans, avec 25 % devenant acquises après un an et le reste devenant acquises mensuellement par la suite, sous réserve d'un emploi continu. Ces subventions relèvent du Plan d'Incitation en Actions de 2020 de Soleno et visent à attirer et retenir les talents conformément à la règle d'inscription Nasdaq 5635(c)(4).
Soleno Therapeutics (NASDAQ: SLNO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung seltener Krankheiten konzentriert, hat Anreize für sechs neue Mitarbeiter angekündigt, wie es die Regeln des Nasdaq Stock Markets erfordern. Die unabhängigen Vorstandsmitglieder des Unternehmens genehmigten nicht qualifizierte Aktienoptionen zum Kauf von 143.850 Aktien des Stammkapitals. Diese Optionen haben Ausübungspreise von $49.52 und $48.44 pro Aktie, die den Schlusskursen von Soleno am 13. und 16. August 2024 entsprechen.
Die Optionszusagen werden über vier Jahre verteilt, wobei 25% nach einem Jahr und der Rest danach monatlich fällig werden, vorausgesetzt die Beschäftigung wird fortgesetzt. Diese Gewährungen fallen unter Solenos Plan für Anreizkapitalbeteiligungen aus dem Jahr 2020 und sind darauf ausgelegt, Talente zu gewinnen und zu halten, gemäß der Nasdaq-Listingregel 5635(c)(4).
- Soleno is attracting new talent, potentially strengthening its workforce
- The company is utilizing equity incentives to align employee interests with shareholders
- Potential dilution of existing shareholders due to the issuance of new stock options
REDWOOD CITY, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to six new employees.
The independent members of the Board of Directors of Soleno approved the grant of non-qualified stock options to purchase 143,850 shares of common stock to six employees as an inducement for them entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company recently submitted an NDA to the FDA, supported by its Phase 3 development program, for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS). For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
FAQ
How many new employees received inducement grants from Soleno Therapeutics (SLNO)?
What is the total number of shares covered by the stock options granted by Soleno Therapeutics (SLNO)?
What are the exercise prices for the stock options granted by Soleno Therapeutics (SLNO) on August 13 and 16, 2024?
What is the vesting schedule for the inducement stock options granted by Soleno Therapeutics (SLNO)?
